Vol.

No.

May 15, 2020May 15, 2020

Free

DOWNLOAD THE PDF

Nancy Davidson describes plans for reopening the Seattle Cancer Care Alliance as COVID-19 wave recedes

Cover Story

Conversation with The Cancer Letter COVID-19 & Cancer Free

Nancy Davidson describes plans for reopening the Seattle Cancer Care Alliance as COVID-19 wave recedes

By Paul Goldberg

Nancy Davidson is now in the eleventh week of managing the COVID-19 pandemic—the longest stretch experienced by any health executive in the U.S.

COVID-19 & Cancer Free

With $306M for serology research, NCI mobilizes labs, academic centers, grantees, contractors, and SBIR

By Paul Goldberg

COVID-19 & Cancer Free NCI

Sharpless: COVID-19 threatens to reverse long-running trend of decreasing cancer mortality

By Matthew Bin Han Ong

Free

NCI BSA approves 11 new and reissue concepts, defers one

By Alexandria Carolan

COVID-19 & Cancer Free Guest Editorial

SARS-CoV-2 and oncology drugs
What do we mean when we talk about value?

By Garth W. Strohbehn, Daniel A. Goldstein and Mark J. Ratain

Free Obituary

Isaiah Fidler, founder of MD Anderson Department of Cancer Biology, dies at 83

Free Obituary

The Class of 1983; Remembering Josh Fidler

By Irwin H. Krakoff and Rosemary Mackey

Free Obituary

Oncology pioneer John W. Yarbro dies at 88

By Eric T. Rosenthal and Donald L. "Skip" Trump

COVID-19 Updates

Heartland NCORP sites implement drive-through laboratory service

Roswell Park to assess immunotherapy combination in cancer patients with COVID-19

MSK Kids study: Children with cancer are not at a higher risk for COVID-19 infection or morbidity

GRYT Health and BMS launch COVID-19 Advocacy Exchange

In Brief

ASCO highlights: 2020 annual meeting scientific program lineup

Long, Smith, Quinn named to new positions at Roswell Park

DFCI and Silverberry Genomix form population health initiative for research and education

Paczesny, Mehrotra named co-leaders of cancer immunology at Hollings Cancer Center

Clinical Roundup

Atezolizumab combination improves survival in HCC

Drugs & Targets

FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations

FDA approves Lynparza + bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 46 - December 19, 2025

Nancy Davidson describes plans for reopening the Seattle Cancer Care Alliance as COVID-19 wave recedes

With $306M for serology research, NCI mobilizes labs, academic centers, grantees, contractors, and SBIR

Sharpless: COVID-19 threatens to reverse long-running trend of decreasing cancer mortality

NCI BSA approves 11 new and reissue concepts, defers one

SARS-CoV-2 and oncology drugs
What do we mean when we talk about value?

Isaiah Fidler, founder of MD Anderson Department of Cancer Biology, dies at 83

The Class of 1983; Remembering Josh Fidler

Oncology pioneer John W. Yarbro dies at 88

COVID-19 Updates

Heartland NCORP sites implement drive-through laboratory service

Roswell Park to assess immunotherapy combination in cancer patients with COVID-19

MSK Kids study: Children with cancer are not at a higher risk for COVID-19 infection or morbidity

GRYT Health and BMS launch COVID-19 Advocacy Exchange

In Brief

ASCO highlights: 2020 annual meeting scientific program lineup

Long, Smith, Quinn named to new positions at Roswell Park

DFCI and Silverberry Genomix form population health initiative for research and education

Paczesny, Mehrotra named co-leaders of cancer immunology at Hollings Cancer Center

Clinical Roundup

Atezolizumab combination improves survival in HCC

Drugs & Targets

FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations

FDA approves Lynparza + bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login